Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
Panelists discuss how referral types for multiple myeloma patients vary widely, including newly diagnosed cases, relapsed/refractory disease, and specific therapy considerations like bispecifics, with processes differing between in-state and out-of-state referrals due to logistical and insurance factors.
EP: 1.The Power of Partnership: Enhancing Patient Care in Multiple Myeloma through Academic and Community Physician Collaboration
EP: 2.Fast-Tracking Care: Streamlining Referrals for Quicker Treatment in Multiple Myeloma
EP: 3.Collaborative Care vs. Independent Treatment: Does It Impact Patient Outcomes in Multiple Myeloma?
EP: 4.Overcoming Challenges in Patient Referrals: Handling Reluctance and Navigating Barriers to Academic Care
EP: 5.When Is the Right Time? Navigating Key Moments for Referring Multiple Myeloma Patients to an Academic Center
EP: 6.Identifying and Referring Candidates for Bispecific Therapy: Key Factors in Transitioning from Community to Academic Care
EP: 7.Navigating the Challenges: Transitioning Patients from Community to Academic Settings in Multiple Myeloma Care
EP: 8.Inside the Academic Approach: How Initial Consultations for Bispecific Therapy Referrals Are Handled
EP: 9.Comparing Dosing and Management of BCMA vs Non-BCMA Bispecific Antibodies
Now Viewing
EP: 10.Management of Bispecifc AE’s in the Community Setting of Multiple Myeloma Patients
Video content above is prompted by the following:
- What types of referrals do you usually do?
- Is the process similar/different for in-state vs out-state?
- Dr Saspu and Dr Shunyakov: How do social factors play into the referral process?
- Dr Saspu and Dr Shunyakov: How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
- How are they managed?
Recent Videos
